BioAtla Inc BCAB Stock Analysis
- OTCMKTS
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.00 down $0.09, 4.31% at close Nov 6
Last close · Previous close $2.09
- Market cap
- $3.31MAt the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$2.00up $0.65, 48.15%Past month
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.09Nov 5
- Volume6.40KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume5.60KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $1.07 to $71.50; now $2.00
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
BCAB beat the S&P 500 in 1 of 6 periods.
| Period | BCAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BCAB: up 48.1% S&P 500: down 5.6% | BCAB beat the S&P 500 by 53.7 percentage points Beat |
| 3M | BCAB: down 39.9% S&P 500: down 4.1% | BCAB trailed the S&P 500 by 35.8 percentage points Trailed |
| YTD | BCAB: down 93.0% S&P 500: up 8.7% | BCAB trailed the S&P 500 by 101.7 percentage points Trailed |
| 1Y | BCAB: down 93.8% S&P 500: up 10.9% | BCAB trailed the S&P 500 by 104.7 percentage points Trailed |
| Long term | ||
| 3Y | BCAB: down 97.8% S&P 500: up 75.0% −72.1% vs +20.5% a year | BCAB trailed the S&P 500 by 172.8 percentage points Trailed |
| 5Y | BCAB: down 99.9% S&P 500: up 67.8% −73.5% vs +10.9% a year | BCAB trailed the S&P 500 by 167.7 percentage points Trailed |
$10,000 invested in BCAB 5 years ago (Nov 5, 2021) would be worth about $13 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $16,782.
BCAB beat the S&P 500 in 1 of 6 periods.
| Period | BCAB and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | BCAB: up 48.1% S&P 500: down 5.6% | BCAB beat the S&P 500 by 53.7 percentage points Beat |
| 3M | BCAB: down 39.9% S&P 500: down 4.3% | BCAB trailed the S&P 500 by 35.6 percentage points Trailed |
| YTD | BCAB: down 93.0% S&P 500: up 7.8% | BCAB trailed the S&P 500 by 100.8 percentage points Trailed |
| 1Y | BCAB: down 93.8% S&P 500: up 9.7% | BCAB trailed the S&P 500 by 103.5 percentage points Trailed |
| Long term | ||
| 3Y | BCAB: down 97.8% S&P 500: up 68.8% −72.1% vs +19.1% a year | BCAB trailed the S&P 500 by 166.6 percentage points Trailed |
| 5Y | BCAB: down 99.9% S&P 500: up 56.9% −73.5% vs +9.4% a year | BCAB trailed the S&P 500 by 156.8 percentage points Trailed |
$10,000 invested in BCAB 5 years ago (Nov 5, 2021) would be worth about $13 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $15,694.
All-time high
$3,545.50
Closing high on . Now 99.9% below that record.
Split-adjusted daily closes since Dec 16, 2020.
Stock splits
1
1-for-50 on . Share counts adjust after each split.
Valuation
The Nov 6 close compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated. Per-share results and the measures based on them are paused. See the note under the price.
Price-to-earnings (P/E)
Paused
Other valuation measures
- 0.4×Last 12 months’ revenue
Market value divided by revenue over the last 12 months. Useful when earnings are small or negative.
P/S = Market cap ÷ Revenue (last 12 months)Price-to-sales ratio - Price-to-bookPausedBook value as of Jun 30, 2026
See the note under the price. - PEG ratioPausedLast 12 months’ EPS growth
See the note under the price. - −708.60%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $7.63MAt the Nov 6 close
What it would cost to buy the whole business: the market cap at the Nov 6 close, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own BCAB DCF in Excel. Value BioAtla with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $8.50Mdown 22.7%
- Net income
- −$31.45M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $11.00M | −$10.59M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$14.88M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$15.33M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$18.71M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$15.78M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $2.00M | −$9.78M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$6.34M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $6.50M | $452.00K | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $250.00K | −$95.40M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $0.00 | −$106.48M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $0.00 | −$123.46M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $11.00M | −$69.78M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $2.00M | −$59.61M | Paused See the note under the price. |
Margins
- Gross 100.0%
- Operating −377.9%
- Net −370.0%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$23.48MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$23.48MLast 12 months
- Capital spending$0.00Last 12 months
- −276.3%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $717.00KLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$717.00KLast 12 months
Balance sheet
- $1.54MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$5.86MAs of Jun 30, 2026
- Net debt$4.32MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.20As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio
Financial strength
- 2 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✗Return on assets improved: not passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −263.2%Last 12 months
Over the last 12 months, BioAtla’s net loss was 263.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About BioAtla Inc
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- OTCMKTS
- Asset type
- Common stock
- Price history since
BCAB news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
BCAB stock FAQ
What is BCAB stock’s price today?
BioAtla (BCAB) traded at $2.00 at the close on , down $0.09 (4.31%) from the previous close of $2.09. Over the past 52 weeks it has traded between $1.07 and $71.50.
If you invested $1,000 in BCAB 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in BCAB on would be worth about $1 at the close on , a total return of −99.9%. The same $1,000 would be worth $62 if invested one year ago. Past performance doesn’t predict future returns.
What is BioAtla’s market cap?
BioAtla’s market capitalization is about $3.3 million. That’s Tiingo’s daily market cap for , at that day’s closing price of $2.00 (how market cap works).
How much revenue does BioAtla make?
BioAtla reported $8.5 million of revenue over the four quarters to , down 22.7% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $6.5 million.
Is BioAtla profitable?
Not over the four quarters to . BioAtla reported a net loss of $31.5 million across those four quarters on $8.5 million of revenue.
Does BCAB pay a dividend?
BioAtla hasn’t paid a dividend in the last twelve months.
What is BCAB’s 52-week high and low?
Over the past 52 weeks BCAB has traded as low as $1.07 and as high as $71.50. At $2.00 at the close on , it is 97.2% below that high and 86.9% above the low.
What is BCAB’s all-time high?
BCAB’s highest closing price was $3,545.50 on , adjusted for stock splits. At $2.00 at the close on , it is 99.9% below that record.
Has BCAB stock ever split?
Yes, once: 1-for-50 on .
How has BCAB stock performed?
Including dividends and measured to the close on , BCAB has returned −93.0% so far this year and −93.8% over the past year, and −99.9% over five years (−73.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is BioAtla in?
BioAtla is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does BCAB trade on?
BioAtla trades on the OTCMKTS under the ticker symbol BCAB. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.